The Differences And Clinical Significance Of Expression Of Glutathion-S-Transferases-Π And Topoisomerase IIΑ In Different Parts Of Oral Squmous Cell Carcinoma

Objectives:We studied the difference of expression of glutathion s-transferases-πand topoisomerase IIαbetween the two parts of the resected samples of oral squamous cell carcinoma .we divided the resected samples into two parts and discussed the difference of drug resistance in different areas and the clinical significance. Methods: We studied 39 samples of oral squamous cell carcinoma, including 20 from patients who did not received chemotherapy and 19 from patients who had received chemotherapy. We had detected the expression of GST-πand Top IIαin surface layer areas and deep invasive areas immunohistology, and detected the expression of GST-πand Top IIαof 5 fresh samples by both immunohistology and flow cytometery. Results:In the surface layer areas of 20 oral squamous cell carcinoma samples which were from patients who did not received chemotherapy, the expression of GST-πand Top IIαwas detected respectively in 18 (90%) and 15(75%), in the deep invasive areas the expression of GST-πand Top IIαwas detected respectively in 15 (75%) and 1(5%). In the surface layer areas of 19 oral squamous cell carcinoma samples which were from patients who had received chemotherapy, the expression of GST-πand Top IIαwas detected respectively in 16 (84.21%) and 18(94.74%), in the deep invasive areas the expression of GST-πand Top IIαwas detected respectively in 12 (63.16%) and 8(42.11%). The differences of GST-πand Top IIαexpression are significant between in surface layer areas and deep invasive areas (P<0.05). Between specimens without chemotherapy and ones with chemotherapy, the differences of GST-πexpression in deep invasive areas are significant, the differences of Top IIαexpression are significant in both surface layer areas and deep invasive areas (P<0.05). In the surface layer areas the rate of the percent of positive cells which expressed GST-πand Top IIαof 5 fresh specimens by flow cytometry was respectively 3.676% and 4.656%, in the deep invasive areas the rate was respectively 5.586% and 3.482%. In the surface layer areas the rate of the percent of positive cells which expressed Gst-πand Top IIαof 5 fresh specimens by immunohistology was respectively 45.176 % and 9.958 %, in the deep invasive areas the rate was respectively 19.148 % and 4.626 %.The differences of GST-πand Top IIαexpression in different areas are significant by flow cytometry (P>0.05). The differences of GST-πand Top IIαexpression in different areas are significant by immunohistology (P<0.05). The expression of GST-πand Top IIαin surface layer areas and deep invasive areas of tumor samples has no relation to the sex and age, histologic grading, the clinical substage and 3-year disease-free survival of patients, the site of tumor and the effect of chemtherapy Conclusions : 1 The differences of GST-πand Top II αexpression in squamous cell carcinoma specimens are significant between in surface layer areas and deep invasive areas, indicating that heterogeneity of drug resistance gene and its associated proteins exists in squamous cell carcinoma. 2 Between specimens without chemotherapy and ones with chemotherapy, the differencesof GST-πexpression in deep invasive areas are significant and the differences of Top IIαexpression are significant in both surface layer areas and deep invasive areas. The results show that drug resistance gene of tumor changes after inducing chemotherapy and it is maybe instructional for us to choose inducing chemotherapy and assistant chemotherapy. 3 The expression of GST-πand Top IIαin surface layer areas and deep invasive areas of tumor samples has no relation to the sex and age, histologic grading, the clinical substage and 3-year disease-free survival of patients,the site of tumor and the effect of chemerapy. so the two marks can not prognosticate chemotherapy effect and prognosis of squamous cell carcinoma patients. 4 Whether drug resistance of squamous cell carcinoma patients gives priority to primary or acquired drug resistance needs more study. 5 The research of drug-resistance heterogeneity in surface layer areas and deep invasive areas of squamous cell carcinoma patients has a few referenced value.